Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Net Margin (2016 - 2025)

Historic Net Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to 64.13%.

  • Enanta Pharmaceuticals' Net Margin rose 673000.0% to 64.13% in Q4 2025 from the same period last year, while for Dec 2025 it was 106.64%, marking a year-over-year increase of 506400.0%. This contributed to the annual value of 125.19% for FY2025, which is 461000.0% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Net Margin of 64.13% as of Q4 2025, which was up 673000.0% from 122.9% recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Net Margin peaked at 64.13% during Q4 2025, and registered a low of 211.62% during Q1 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' median Net Margin value was 139.95% (recorded in 2023), while the average stood at 146.28%.
  • Its Net Margin has fluctuated over the past 5 years, first crashed by -1583900bps in 2021, then surged by 807000bps in 2024.
  • Enanta Pharmaceuticals' Net Margin (Quarter) stood at 108.92% in 2021, then decreased by -13bps to 122.9% in 2022, then crashed by -51bps to 185.56% in 2023, then rose by 29bps to 131.43% in 2024, then soared by 51bps to 64.13% in 2025.
  • Its last three reported values are 64.13% in Q4 2025, 122.9% for Q3 2025, and 99.68% during Q2 2025.